Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital Changes
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Net Income: 2010-2024

Historic Net Income for China Pharma Holdings (CPHI) over the last 15 years, with Dec 2024 value amounting to -$4.7 million.

  • China Pharma Holdings' Net Income rose 41.72% to -$651,482 in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.2 million, marking a year-over-year increase of 32.76%. This contributed to the annual value of -$4.7 million for FY2024, which is 53.84% down from last year.
  • Per China Pharma Holdings' latest filing, its Net Income stood at -$4.7 million for FY2024, which was down 53.84% from -$3.1 million recorded in FY2023.
  • Over the past 5 years, China Pharma Holdings' Net Income peaked at -$2.9 million during FY2020, and registered a low of -$4.7 million during FY2024.
  • In the last 3 years, China Pharma Holdings' Net Income had a median value of -$4.0 million in 2022 and averaged -$3.9 million.
  • As far as peak fluctuations go, China Pharma Holdings' Net Income soared by 86.15% in 2020, and later slumped by 53.84% in 2024.
  • Yearly analysis of 5 years shows China Pharma Holdings' Net Income stood at -$2.9 million in 2020, then fell by 18.58% to -$3.4 million in 2021, then dropped by 16.87% to -$4.0 million in 2022, then climbed by 22.50% to -$3.1 million in 2023, then crashed by 53.84% to -$4.7 million in 2024.